'Sensitive outstanding issues' delay adoption of EMA clinical trial data disclosure policy
This article was originally published in SRA
Executive Summary
Unable to decide on the final wording of the European Medicines Agency's controversial policy on the publication of clinical trial data, the agency's management board has delayed until 2 October its formal adoption of the policy1.